A recently-released study from the Harvey L. Neiman Health Policy Institute (HPI) and American College of Radiology (ACR) Data Science Institute (DSI) projects that new U.S. Food and Drug Administration (FDA)-approved artificial intelligence (AI) medical imaging products will increase five-fold by 2035.
Estimated rates of lung cancer screening with low-dose CT were extremely low among eligible patients across insurance types in 2017, with rates varying between patient demographics.